Ben Veghte


WASHINGTON, DC – The National Venture Capital Association (NVCA) issued the following statement today after the Senate Committee on Health, Education, Labor and Pensions (HELP) voted to advance the nomination of Scott Gottlieb, M.D. for Commissioner of the Food and Drug Administration (FDA).  A Resident Fellow at the American Enterprise Institute (AEI), Gottlieb has deep experience in the venture industry, previously serving as a venture partner in life sciences startups at New Enterprise Associates (NEA).

“With Dr. Gottlieb’s nomination moving forward to the full Senate for confirmation, the FDA should very soon have a leader in place who has substantial experience and knowledge of the medical innovation ecosystem,” said Bobby Franklin, President and CEO of NVCA. “Dr. Gottlieb understands the progress that has been made over the last several years in reforming the regulatory environment for medical innovation as well as the steps that still need to be taken to improve government regulations and processes to ensure the U.S. continues to be at the forefront of developing solutions to diagnose, treat and cure deadly diseases. We congratulate Dr. Gottlieb on his advancement and look forward to working with him to improve the regulatory environment for healthcare startups.”

About National Venture Capital Association

Venture capitalists are committed to funding America’s most innovative entrepreneurs, working closely with them to transform breakthrough ideas into emerging growth companies that drive U.S. job creation and economic growth. As the voice of the U.S. venture capital community, the National Venture Capital Association (NVCA) empowers its members and the entrepreneurs they fund by advocating for policies that encourage innovation and reward long-term investment. As the venture community’s preeminent trade association, the NVCA serves as the definitive resource for venture capital data and unites its member firms through a full range of professional services. For more information about the NVCA, please visit